Withdrawing
• Withdraw Lipiodol® Ultra Fluid and anticancer drug into the 2 mixing syringes
• Connect the mixing syringes to the 4 ports 3 way stopcock
• Anticancer drug should be first pushed towards the syringe containing Lipiodol®
Vectorio® - Lipiodol® Resistant Mixing & Injection System for cTACE
Vectorio® resist Lipiodol® up to 24H(1), Guerbet recommends the use of Vectorio® to prepare and inject the mixture of Lipiodol® and anticancer drug.
Video of using Vectorio in cTACE procedure
Know more about mixture preparation recommendations (2)
• Anticancer drug should be first pushed towards the syringe containing Lipiodol®
• Anticancer drug volume should be lower than Lipiodol® volume, ideally 1 drug volume to 2 Lipiodol® volumes
• Vigorous mixing of Lipiodol® & anticancer drug via the stopcock
Lipiodol® Ultra Fluid may be associated with various anticancer drugs
| Anticancer drugs that may be associated with Lipiodol ® Ultra Fluid* | |||
| Cisplatin | Doxorubicin | Epirubicin | Mitomycin |
*The instructions and precautions for use relating to anticancer drugs must be strictly followed
Features and benefits
|
|
Features Benefits |
|
|
Features Benefits |
|
|
Features •Safety – Reduced risks of infection, air injection, leaks(3) •Swiftness – less connection mistakes & no disconnection time •Convenience – On-table Mixing & optimized injection control |
Know more about Vectroio performance - Read the full brochure
Use Vectorio for cTACE mixture preparation
Mixing
• Perform 20 vigorous back & forth movements to obtain an homogeneous mixture
Injecting
• Connect stopcock to the microcatheter
• Lipiodol® Ultra Fluid + anticancer drug mixture ready to inject
• Possibility of remixing, refill within closed system (on-table mixing)
Compounds
Vectorio compounds
Function of Vectorio® has been validated for resistance to Lipiodol® up to 24h(1)
A & B 20 mL mixing syringes (x2)
C Particle filter for Lipiodol® Ultra Fluid withdrawal (x1)
D Lipiodol® Ultra Fluid ampoule withdrawing straw (x1)
E Lipiodol® Ultra Fluid vial spike (x1)
F 3-way stopcock with 4 connections (x1)
G Connector (x1)
H 1 mL injection syringe (x1)
I 3 mL injection syringe (x1)
The system does not contain:
- Lipiodol® Ultra Fluid ampule or vial
- Anticancer drug
- Microcatheter
A & B: Mixing syringes (20 mL) – Design Aim – Making multiple mixes easy & safe
C: Particle filter for withdrawing Lipiodol®
Design Aim – Easy & safe to perform preparation
F: 3-way stopcock with 4 connections-(Patented) – Design Aim – Easy & safe to perform operation
Raw materials – Strong & Resistant for cTACE use
G: Double female connector
Design Aim – Easy & safe to perform preparation
H & I: 1 mL & 3 mL injection syringes – Design Aim- Making injection easy & safe
Education & Resources
Learn moreReferences
1.Test Report E17-41 (2017)
2.Thierry de Baere et al., Treatment of Liver Tumors with Lipiodol TACE: Technical Recommendations from Experts Opinion. Cardiovasc Intervent Radiol,2016;39:334–343.
3.Internal Test Report E20-13 (2020)
P20000256